Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
May 20, 2020
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
May 19, 2020
Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
May 12, 2020
Ocular Therapeutix™ To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting
May 11, 2020
Ocular Therapeutix™ Reports First Quarter 2020 Financial Results and Business Update
May 08, 2020
Ocular Therapeutix™ To Report First Quarter 2020 Financial Results
April 30, 2020
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
April 28, 2020
Ocular Therapeutix™ Provides Business Update and Response to COVID-19 Global Pandemic
April 13, 2020
Ocular Therapeutix™ Reports Fourth Quarter and Year End 2019 Financial Results and Business Update
March 12, 2020
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2019 Financial Results
March 05, 2020
Ocular Therapeutix™ Announces Preliminary Fourth Quarter 2019 Net Product Revenue and Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial at the Cowen 40th Annual Health Care Conference
March 03, 2020
Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference
February 25, 2020
Ocular Therapeutix™ Presents Data Demonstrating a Clinically-Meaningful Reduction in Intraocular Pressure in Patients with Primary Open Angle Glaucoma or Ocular Hypertension Treated with OTX-TIC at Glaucoma 360 Conference
